England's Medicine Shortage Crisis Is Deepening — and Patients Are Paying the Price

England's Worsening Drug Shortage Is Putting Lives at Risk

Across England, a growing number of patients are walking out of pharmacies empty-handed — not because their prescriptions are wrong, but because the medications they depend on simply aren't available. From epilepsy and Parkinson's Disease to heart conditions, bipolar disorder, and ADHD, hundreds of commonly prescribed drugs have become increasingly difficult to obtain, and experts warn the situation is only getting worse.

A Patient's Nightmare: Living Without Essential Medication

Chloe, 29, has epilepsy and relies on a Lamotrigine-based drug to prevent potentially fatal seizures. In recent weeks, her inability to access the correct medication has had devastating consequences.

"It's just terrifying," she says. "I get panic attacks."

Without her medication, Chloe's seizures returned. She fell, suffered a head injury, and now carries a prominent scar across her back as a permanent reminder of what happens when supply chains fail vulnerable patients. She describes spending hours on public transport, traveling from pharmacy to pharmacy in search of her prescription — a routine she refers to as "going on patrol."

Her story is far from isolated. The Epilepsy Society has identified at least three deaths over the past two years in which a lack of medication was considered a contributing factor.

How the Funding System Is Making Things Worse

At the heart of the crisis lies a deeply flawed funding structure. The NHS reimburses pharmacies at a fixed rate for every drug dispensed. Pharmacies are then required to source those medications at or below that set price.

When global market prices spike above NHS reimbursement rates, drugs are added to the government's price concessions list — a mechanism designed to offer pharmacies temporary financial relief. In April, a record 210 medications appeared on that list simultaneously.

However, the system has a critical flaw. When wholesale prices surge rapidly — sometimes exceeding both the standard NHS tariff and the concession price — pharmacies are forced to dispense drugs at a financial loss. Faced with this reality, many pharmacy owners deliberately limit their stock orders to minimize losses, which in turn reduces the supply available to patients.

The Numbers Behind the Crisis

The financial strain on pharmacies is significant. In Shepperton, Surrey, pharmacist Akash Patel demonstrated the problem firsthand while preparing a monthly prescription for a patient with epilepsy. Unable to source all the required items, Patel noted that even the portion he could supply would leave his pharmacy nearly £9 out of pocket.

One widely used antidepressant, Venlafaxine, illustrates the disparity starkly. The government's reimbursement rate is set at £3.89, yet the cheapest Patel can currently purchase it for is £5.25.

"It's a big loss-making drug, so we only ever order small amounts in the hope the price will come down," he says. "And even when I order it, there's no guarantee it will actually arrive."

Patel, who has been working in pharmacy for years, describes the current situation as the worst he has ever witnessed — and the trend shows no sign of reversing.

Pharmacy Closures Add to the Access Problem

The financial pressure is also accelerating the closure of independent pharmacies across England. Since 2017, approximately 1,500 high street pharmacies have shut their doors, with 27 closures recorded in the current year alone. England now has fewer pharmacies than at any point in the last two decades — a stark reality that further limits access for patients in both urban and rural communities.

Why Drug Prices Are Climbing

Several interconnected global factors are driving pharmaceutical prices higher. Rising energy costs, increasingly expensive international freight, and geopolitical tensions have all pushed up the cost of manufacturing and delivering medicines to the UK. Compounding matters, many drugs are derived from oil-based ingredients, and rising crude oil prices have added further pressure to production costs.

Some manufacturers argue that NHS pricing has been kept artificially low for so long that supplying certain medications to the UK market is no longer commercially viable. When manufacturers reduce or halt supply, wholesale prices rise sharply — creating a cycle that pharmacies and patients are left to absorb.

Parkinson's Patients Among Those Affected

Chris Henry, 49, takes Co-Careldopa to manage his Parkinson's Disease. His medication has also been placed on the government's concessions list. A father of four who works full time, Chris understands better than most what running out of medication would mean for his daily life.

"Trying to manage medication for Parkinson's Disease is a nightmare at the best of times, so thinking there's a shortage is incredibly worrying," he says. "These medications make my life liveable."

After hearing about the emerging shortage, Chris acted quickly and placed his next order early, hoping the supply arrives before his current stock runs out. For many patients in similar situations, that kind of forward planning simply isn't possible.

The Bigger Picture: UK Spending vs. European Peers

Analysts point to a structural issue that underpins the entire problem. Across the UK, total government spending on medicines represents a smaller share of health budgets per patient than in many comparable Western European nations, including France and Germany.

The consequence of this underspending is predictable: when global supplies tighten, pharmaceutical manufacturers will prioritize markets where profit margins are higher. Unless the UK addresses how it values and funds its medicine supply chain, patients will continue to bear the burden of a system struggling to keep pace with demand.